Advisor Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

Advisor Group’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-575	Closed	-$1K	–	5239
2018 Q1	$1K	Hold	575	–	–	﹤0.01%	4924
2017 Q4	$2K	Hold	575	–	–	﹤0.01%	4774
2017 Q3	$2K	Hold	575	–	–	﹤0.01%	4637
2017 Q2	$4K	Hold	575	–	–	﹤0.01%	4382
2017 Q1	$5K	Sell	575 -100	-15%	-$6.33K	﹤0.01%	4169
2016 Q4	$66K	Hold	675	–	–	﹤0.01%	2393
2016 Q3	$67K	Hold	675	–	–	﹤0.01%	2296
2016 Q2	$82K	Buy	+675	New	+$90.1K	﹤0.01%	2067

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Advisor Group's ARGS Position: Q2 2018 in Review

Advisor Group sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 575 shares — an estimated $1K sold.

Advisor Group first reported a position in ARGS in Q2 2016 and held it in 8 quarters. The position peaked at $82K in Q2 2016. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

Advisor Group reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Advisor Group sold 575 Argos Therapeutics, Inc. shares in Q2 2018, an estimated $1K.
Advisor Group first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
Advisor Group's Argos Therapeutics, Inc. position peaked at $82K in Q2 2016.
4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Advisor Group's 13F filing for Q2 2018, filed 13 Aug 2018.